# Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years

> **NCT03179423** · PHASE2 · COMPLETED · sponsor: **GeNeuro Australia PTY Ltd** · enrollment: 64 (actual)

## Conditions studied

- Diabetes Mellitus Type 1

## Interventions

- **DRUG:** GNbAC1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03179423
- **Lead sponsor:** GeNeuro Australia PTY Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-14
- **Primary completion:** 2018-09-01
- **Final completion:** 2019-05-07
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2020-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03179423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03179423, "Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03179423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*